Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants면역의 지속성과 새로운 변이체에 대한 비활성화된 COVID-19 백신 3차 접종의 영향Clinical Trial Published on 2022-07-142022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, [키워드] (alpha Alpha Antibody titers B cell memory Beta booster booster dose Breakthrough infection breakthrough infections Cell mediated immunity clinical concern Controlled trial COVID-19 COVID-19 vaccine COVID-19 vaccines D614G Delta dose double-blind Effectiveness Heterologous homologous humoral humoral and cell mediated immunity Immunity immunogenicity inactivated India injection injection site itching magnitude neutralization titer Neutralizing antibodies neutralizing antibody omicron Pain persistence Phase 2 question Randomized controlled trial recipient redness registry responses Safe Serious Adverse Event Serious Adverse Events slight increase strain Trial registration vaccination variant variants VOCs within 6 months [DOI] 10.1038/s41598-022-16097-3 PMC 바로가기 [Article Type] Clinical Trial
Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals비활성화된 COVID-19 백신에 대한 면역 반응 및 안전성: HIV 감염자와 HIV 감염 경험이 없는 개인 간의 비교Article Published on 2022-07-052022-09-12 Journal: AIDS Research and Therapy [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI Adults Adverse reaction Antibody neutralization Antiretroviral therapy baseline binding antibody unit Biological CD4 chemiluminescence colloidal gold COVID-19 COVID-19 vaccine COVID-19 vaccines effective Efficacy ELISA enrolled Follow-up Frequency geometric geometric mean concentration GMC humoral immune response IgG IgG antibody IgG response immune immune response inactivated Inactivated COVID-19 vaccine individual injection NAb not different observation outcome peaked PLWH PLWH population PLWH. primary immunogenicity product remained response SARS-CoV-2 neutralizing antibody second dose Serious Adverse Events seroconversion rate shown Sinopharm specific IgM with HIV Wuhan [DOI] 10.1186/s12981-022-00459-y PMC 바로가기 [Article Type] Article
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trialSARS-CoV-2 및 S-Trimer(SCB-2019) COVID-19 백신에 대한 이전 노출이 재감염 위험에 미치는 영향: 무작위 배정, 이중 맹검, 위약 대조, 2상 및 3상 시험Clinical Trial Published on 2022-07-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 1:1 95% CI addition Alpha assigned attack rates B.1.1.7 B.1.351 B.1.617.2 B.1.621 baseline Beta calculate CEPI Clover Coalition confirmed case COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccine dose double-blind double-blinded Efficacy enrolled Evidence evidence of exposure to FIVE groups hospitalisation Impact injection site pain Innovation IQVIA Lambda Local lowest moderate-to-severe COVID-19 multicentre no evidence of P.1 participant Participants Phase 2 Placebo placebo-controlled placebo-controlled trial Primary outcome Primary outcomes protection Protective randomised Randomly Rate reactogenicity Real-time PCR receive recipients recombinant Reinfection reported response risk SARS-CoV-2 SARS-CoV-2-naïve participants SCB-2019 Secondary analyses secondary analysis Serious Adverse Event Serious Adverse Events severe adverse events severe COVID-19 severity subsequent subset symptomatic systemic adverse event systemic adverse events technology Trial USA vaccination Vaccine vaccine dose vaccine efficacy variant variants Viral variants with COVID-19 [DOI] 10.1016/S1473-3099(22)00144-X PMC 바로가기 [Article Type] Clinical Trial
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trialResearch article Published on 2022-06-272022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 임상, 치료법, [키워드] 1:1 95% CI administration age Analysis Antibody Response Antibody titre Arthritis assigned atopic dermatitis booster Booster vaccine clinics COVID-19 COVID-19 vaccination COVID-19 vaccination programme COVID-19 vaccine data analyst Dermatology diagnosed domain dose Effect Efficacy evaluated female finding funding geometric geometric mean ratio GMR groups hospital Immune-mediated Immune-mediated inflammatory disease Immune-mediated inflammatory diseases Immunity inflammatory condition inflammatory disease inhibit intention-to-treat population interim analysis Intervention investigators Laboratory low-dose methotrexate mixed-effects model multicentre open label Open-label parallel-group participant Participants Patient platform Primary outcome randomisation randomised Randomly receiving recruited recruitment Registered Research researcher rheumatoid arthritis rheumatology SARS-CoV-2 SARS-COV-2 infection Serious Adverse Events Spike protein spondyloarthritis susceptible systemic lupus erythematosus the SARS-CoV-2 translate Treatment treatment as usual Trial Two-arm vaccination Vaccine vaccine dose Vaccine-induced immunity [DOI] 10.1016/S2213-2600(22)00186-2 [Article Type] Research article
Ivermectin for preventing and treating COVID-19COVID-19 예방 및 치료를 위한 이버멕틴Review Published on 2022-06-212022-09-11 Journal: The Cochrane database of systematic reviews [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Admission adverse event adverse events all-cause mortality antiparasitic Antiviral approach ARMS Asymptomatic certainty certainty of evidence citation classification Clinical improvement clinical trial Cochrane COVID-19 Study Register coronavirus coronavirus disease COVID-19 COVID-19 diagnosis COVID-19 symptoms COVID-19 treatment Data collection database death discharged disease disease severity double-blind duration of symptom early stage early stages Efficacy Efficacy and safety eligible Evidence excluded for inclusion GRADE hospital identify in vitro include increase index Infection infection with SARS-CoV-2 inhibit inhibitory effect initial symptom Inpatient Inpatients Intervention Invasive mechanical ventilation investigated Ivermectin life mean difference Mental Meta-analysis Mild Moderate COVID-19 moderate-to-severe COVID-19 molecular hypothesis Mortality no effect non-randomized ongoing trial ongoing trials Open-label outcome Outpatient outpatients participant Participants people with COVID-19 physical Placebo placebo-controlled Postexposure Prophylaxis Prevent Quality of life question Randomized controlled trial Randomized controlled trials RCT RCTs receiving reduce Registered Replication Reporting request Research resolved risk Risk of bias risk ratio RoB 2 SARS-CoV-2 SARS-COV-2 infection Science Citation Index searched Selection Serious Adverse Event Serious Adverse Events Seven severe acute respiratory syndrome Coronavirus Standard of care treat treated treating COVID-19 Treatment Trial trials viral clearance virus Web of Science WHO WHO guideline worsening [DOI] 10.1002/14651858.CD015017.pub3 PMC 바로가기 [Article Type] Review
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]건강한 개인에서 다양한 COVID-19 백신 조합의 안전성 및 면역원성 평가: 무작위, 피험자 맹검, 대조 3상 시험을 위한 연구 프로토콜 [PRIBIVAC]Article Published on 2022-06-162022-09-11 Journal: Trials [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] adverse event adverse events anti-SARS-CoV-2 antibodies antibody approval best blood sample Blood samples BNT162b2 boost booster booster dose booster vaccinations cellular Cellular immune response collected Combination Comprehensive control arm Controlled clinical trial CoronaVac country COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines demonstration different time point different time points dose Effectiveness Eligible participants Endpoint enrolment evade excluded group healthy Heterologous homologous host immunity humoral immune immune profiling immune response Immunity Immunocompromised immunogenicity Immunoglobulin immunoglobulins Inactivated vaccine Infection Intervention intervention arm Laboratory test Laboratory tests Local maintain mRNA mRNA vaccine mRNA-1273 omicron over parameters participant performed persistence phase Phase 3 phase 3 trial physical population immunity pregnant primary endpoint Probability quantity raising randomization Randomized Randomized controlled trial regimen Regulatory SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event Serious Adverse Events Singapore Study protocol vaccination Vaccine vaccine availability vaccine booster vaccine candidate variants variants of concern volunteers wildtype [DOI] 10.1186/s13063-022-06345-2 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial6~17세 어린이 대상 ChAdOx1 nCoV-19(AZD1222) 백신의 안전성 및 면역원성: 2상 단일 맹검, 무작위, 대조 시험인 COV006의 예비 보고서Clinical Trial Published on 2022-06-112022-09-11 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] 95% CI administration Adults adverse event adverse events age All participants anti-SARS-CoV-2 IgG antibody Antibody titre antibody titres arbitrary unit assigned AstraZeneca AZD1222 baseline capsular Cellular responses ChAdOx1 ChAdOx1 nCoV-19 children chronic respiratory conditions Concentration Controlled trial COVID-19 COVID-19 vaccine COVID-19 vaccines Cutoff Department dose doses Efficacy enrolled Fever first dose first vaccination four group four groups geometric geometric mean geometric mean ratios Geometric means group half-maximal inhibitory concentration Humoral response humoral responses immune response immune responses immunogenic immunogenicity in some intramuscular dose introduced investigators ISRCTN Laboratory laboratory-confirmed Laboratory-confirmed COVID-19 Local nucleocapsid protein Pain and tenderness participant Participants peaked Phase 2 phase 3 study preliminary report Primary outcome prime and boost raised randomised Randomly receive receiving recruitment Registered remained reported resolved respiratory response Safety safety population SARS-CoV-2 second dose second vaccination secondary outcome Serious Adverse Event Serious Adverse Events seronegative seronegative participant seronegative participants seropositive serostatus single-blind stratified study drug study groups tenderness Tolerability treatment allocation Trial vaccination Vaccine Viral viral particle were recorded [DOI] 10.1016/S0140-6736(22)00770-X PMC 바로가기 [Article Type] Clinical Trial
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label TrialSARS-CoV-2 DNA 백신 INO-4800, 1상 공개 라벨 시험에서 강화될 수 있는 내구성 면역 반응 유도Clinical Trial Published on 2022-06-012022-09-12 Journal: The Journal of Infectious Diseases [Category] Coronavirus, COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] activated acute respiratory syndrome Adults adverse event age Antibody Response Antigen being booster booster dose CD8+ T cell clinical clinical trial coronavirus coronavirus disease COVID-19 DNA DNA vaccine dosage dose effective Electroporation evaluated Frequency full-length healthy homologous immune response immune responses immunogenicity increase in INO-4800 intradermal injection Mild MOST pandemic Participants Phase 1 primary dose response Safe Safety SARS-CoV-2 second dose Serious Adverse Events significantly increased subsequent Support T cell Trial Vaccine [DOI] 10.1093/infdis/jiac016 PMC 바로가기 [Article Type] Clinical Trial
Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot studyClinical Trial Published on 2022-05-262022-10-04 Journal: Stem Cell Research & Therapy [Category] 임상, [키워드] adipose administration adverse event adverse events assigned chest imaging Clinical characteristics clinical study COVID-19 COVID-19 patient COVID-19 patients D-dimer daily dose demographic data dose Efficacy Efficiency enrolled event Evidence Exosome Exosomes Extracellular vesicles feasible females Hospital admission IL-6 incidence inhalation interquartile range IQR laboratory result Lymphocyte count male median median age median time Mesenchymal stromal cell. MSC nebulized onset of symptom Patient patients patients with COVID-19 pilot study Pneumonia Primary outcome pulmonary lesion receive safety profile Serious Adverse Events serum Seven severe COVID-19 single-arm slight increase stromal cell supported tested tissue Toxicity Treatment Trial Vesicle vesicles Wuhan, China [DOI] 10.1186/s13287-022-02900-5 PMC 바로가기 [Article Type] Clinical Trial
Study protocol for a single-centre randomised controlled trial to investigate the effect of lung recruitment in paediatric patients after cardiac surgery심장 수술 후 소아 환자에서 폐 모집의 효과를 조사하기 위한 단일 센터 무작위 대조 시험에 대한 연구 프로토콜Article Published on 2022-05-172022-09-11 Journal: BMJ Open [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory distress acute respiratory distress syndrome after cardiac surgery approval arrhythmia arterial oxygen tension article barotrauma cardiac Cardiac surgery China clinical trial Compliance conferences Critical Critical care decrease determine Ethics ethics committee fraction guidelines Hospital stay Hypotension hypoxaemic respiratory failure IMPROVE Intensive intensive care intensive care unit lung recruitment mechanical ventilation Mortality non-invasive ventilation Occurrence oxygen Oxygenation Paediatric cardiac surgery Paediatric intensive & paediatric patient paediatric patients PaO Patient peer-reviewed postoperative primary endpoint protocol protocols protocols & pulmonary complications randomised controlled trial Randomly reduce registration number respiratory distress Respiratory failure Respiratory system secondary endpoint Secondary endpoints Serious Adverse Event Serious Adverse Events syndrome Trial university Ventilator-free days West [DOI] 10.1136/bmjopen-2022-063278 PMC 바로가기 [Article Type] Article